Pharmacometric Analysis of Intranasal and Intravenous Nalbuphine to Optimize Pain Management in Infants
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pediatrics"
DOI: 10.3389/fped.2022.837492
Abstract: Objectives The objective of this pharmacometric (PMX) study was to (i) characterize population pharmacokinetics (PPK) and exposure-pain response associations following intranasal (0.1 mg/kg) or intravenous (IV, 0.05 mg/kg) administration of nalbuphine, with the goal to… read more here.
Keywords: optimize pain; intranasal; pain; pharmacometric analysis ... See more keywords